Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD34 Double Nickase Plasmid (h): sc-400197-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD34 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD34 Double Nickase Plasmid (h) and CD34 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD34. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD34 Antibody (B-6): sc-74499
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD34 Double Nickase Plasmid (h) | sc-400197-NIC | 20 µg | $410.00 | |||
CD34 Double Nickase Plasmid (h2) | sc-400197-NIC-2 | 20 µg | $410.00 |
CD34 is a sialomucin-like transmembrane glycoprotein widely used as a marker of human hematopoietic stem and progenitor cells and is also expressed on vascular endothelium and select stromal populations. It contributes to cell adhesion and trafficking by modulating interactions with selectins and extracellular matrix components, influencing migration, homing, and niche retention. Through effects on membrane organization and signaling at the cell surface, CD34 is linked to processes governing hematopoietic development, endothelial biology, and inflammatory cell recruitment. Altered CD34 expression patterns are relevant to studies of hematologic malignancies, vascular remodeling, and stem cell dynamics in disease models.
CD34 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD34 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD34. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD34 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD34-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.